Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| HUTCHMED (China) Limited | Savolitinib + TAGRISSO (osimertinib) - (SAVANNAH) | Non-small cell lung cancer (NSCLC) | Phase 2 | Data Released | Oral | Oncology |
| HUTCHMED (China) Limited | Fruquintinib in combination with Sintilimab - (FRUSICA-2) | 2L renal cell carcinoma | Phase 2/3 | Data Released | Oral and intravenous | Oncology |
| HUTCHMED (China) Limited | SULANDA (surufatinib) with camrelizumab (C), nab-paclitaxel and gemcitabine (AG) | Metastatic pancreatic ductal adenocarcinoma (PDAC) in China | Phase 2/3 | Ongoing | Oral and intravenous | Oncology |
| IDEAYA Biosciences Inc. | Darovasertib - (neo-adjuvant and adjuvant settings) - (NADOM) | Ocular Melanoma | Phase 2 | Data Released | Oral | Oncology |
| IDEAYA Biosciences Inc. | IDE397 and Trodelvy | Solid Tumors | Phase 2 | Data Released | IDE397 oral Trodelvy intravenous | Oncology |
| IDEAYA Biosciences Inc. | Darovasertib - (IDE196-009) | Uveal Melanoma | Phase 2 | Data Released | Oral | Oncology |
| IDEAYA Biosciences Inc. | Darovasertib (IDE196) - (basket) | Solid tumors | Phase 2 | oral | Oncology | |
| IDEAYA Biosciences Inc. | Darovasertib (neoadjuvant) - (OptimUM-10) | Uveal melanoma (UM) | Phase 3 | Ongoing | Oral | Oncology |
